评估CYP2C19临床决策支持警报指南P2Y12抑制剂处方
Ashley N Springer1, Leah A Alicea1, Yemi Gafari1
1Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Clinical pharmacology and therapeutics
|May 12, 2025
概括
对CYP2C19遗传学的临床决策支持警报在PCI后改善了P2Y12抑制剂的处方. 虽然接受程度各不相同,但警报指导了一些患者使用非皮格瑞尔,显示了个性化医疗的潜力.
科学领域:
- 药物基因组学 药物基因组学
- 临床信息学 临床信息学
- 心脏病学 心脏病学
背景情况:
- CYP2C19遗传变异会影响经皮冠状动脉干预 (PCI) 患者的克洛皮多格雷尔疗效.
- 个性化的P2Y12抑制剂选择对于PCI后的最佳抗血小板治疗至关重要.
研究的目的:
- 评估处方者对临床决策支持 (CDS) 警告的反应,建议基于CYP2C19基因型的替代P2Y12抑制剂.
- 评估CDS警报对PCI后患者基因型导向P2Y12抑制剂处方的影响.
主要方法:
- 对2020年10月至2023年12月的警报响应和P2Y12抑制剂处方数据的回顾性分析.
- 对362名患有CYP2C19-clopidogrel的患者进行的评估显示PCI后的CDS警报.
- 对CYP2C19低代谢和中等代谢者之间的警报接受率的比较.
主要成果:
- 警告建议在24.5%的时间内被接受,导致在PCI后22.4%的天使用替代P2Y12抑制剂.
- 警报接受度对于较差的代谢者来说比中间代谢者高 (P=0.03).
- 提供者的临床判断是超越警报的最常见原因 (68%).
结论:
- 由CYP2C19引导的CDS警告部分促进基因型引导的P2Y12抑制剂,处方PCI后.
- 随着年龄的增长和同时使用口服抗凝剂,警报接受度降低.
- 需要进一步的研究,以了解处方者覆盖的原因,并优化CDS的实施.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
392
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
392
Pharmacovigilance
744
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
744
Cardiovascular Drugs: Classification based on Therapeutic Indications
1.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
1.9K
Antidepressant Drugs: Overview
321
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
321
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
383
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
383
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
92
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
92


